Zobrazeno 1 - 6
of 6
pro vyhledávání: '"David Bartlett"'
Autor:
Louis D Falo, Xingxing Hao, Guo Chen, Cara D Carey, Zuqiang Liu, David Bartlett, Walter J Storkus, Zhaoyang You
Publikováno v:
The Journal of Immunology. 206:57.25-57.25
Blockade of immune checkpoint PD1 in cancer patients results in remarkable therapeutic benefits. Revealing mechanisms underlying this revolutionary therapy is critical to identifying biomarkers for predicting responses to this treatment and developin
Publikováno v:
The Journal of Immunology. 192:73.1-73.1
Type-1 immune responses, mediated by IFNγ and TNFα-producing CTLs, Th1, and NK cells, are essential for effective anti-tumor immunity. Despite recent advances in the induction and stabilization of these responses by cancer immunotherapies, the clin
Autor:
Yukai He, Yuan Hong, Yibing Peng, Lisa Butterfield, Sheng Guo, David Bartlett, David Munn, Jose Guevara-Patino, Junfeng Pang, Nahid Mivechi
Publikováno v:
The Journal of Immunology. 192:206.4-206.4
In this study, we investigated whether alpha-fetoprotein (AFP) and glypican 3 (GPC3) could be engineered to create effective vaccines to potently activate CD8 T cells to prevent clinically relevant carcinogen-induced autochthonous hepatocellular carc
Autor:
Pawel Kalinski, Ravikumar Muthuswamy, Natasa Obermajer, Herbert Zeh, Amer Zureikat, Robert Edwards, David Bartlett
Publikováno v:
The Journal of Immunology. 190:140.10-140.10
Type-1 immune effector cells (CTLs, Th1 and NK cells) express high levels of CXCR3 and CCR5 and depend on the relevant chemokine ligands (CXCL9, CXCL10 and CCL5) for entry into tumor microenvironments. We observed that local production of prostagland
Publikováno v:
The Journal of Immunology. 190:205.16-205.16
Oncolytic vaccinia virus (VV) therapy has shown promise in preclinical models and in clinical studies. Complete responses, however, have rarely been observed. The limitations presented by VV therapy typically have been suboptimal virus spread through
Autor:
Pawel Kalinski, Howard Edington, Charles Brown, Theresa Whiteside, Lisa Butterfield, David Bartlett, John Kirkwood
Publikováno v:
The Journal of Immunology. 182:41.51-41.51
Continuous intralymphatic delivery of dendritic cells (DCs), using implantable lymphatic cannulas, allows to efficiently deliver "non-exhausted" DCs to draining lymph nodes without the disruption of nodal structures, and to recreate the physiologic k